VTP50469 (VTP-50469) is a novel, oral and potent inhibitor of Menin-MLL protein protein interaction (Ki = 104 pM) with potential anticancer activity. Inhibition of the menin(MEN) and MLL1(KMT2A) interaction reverses
leukemic gene expression driven by MLL-fusion proteins and is a
potential targeted therapeutic strategy in MLL-rearranged AML.
纯度:≥98%
CAS:2169916-18-9